Abstract
The incidence of therapy-related myelodysplastic syndromes (t-MDS) has been increasing with the widespread use of highly active antiretroviral therapy (HAART) therapy for HIV and chemotherapy for AIDS-related cancers. The classical dysplastic features in the granulocytes and megakaryocytes may not be easily appreciated. The most reliable distinguishing feature between the hematopoietic dysplasia of t-MDS and that of HIV infection rests on the identification of MDS-related cytogenetic aberrations. Here we report a patient with well-controlled HIV and history of chemotherapy for invasive anal squamous cell carcinoma who developed high-risk t-MDS with complex chromosome abnormalities. Our study emphasizes the importance of diagnosis of MDS in HIV-infected patients, even in the absence of dysplasia, if there are typical cytogenetics changes of MDS. Therefore, the early diagnosis and intervention of t-MDS in HIV-positive patients are critical in the treatment of this aggressiveness disease.
Original language | English (US) |
---|---|
Pages (from-to) | 213-214 |
Number of pages | 2 |
Journal | Journal of Hematopathology |
Volume | 12 |
Issue number | 4 |
DOIs | |
State | Published - Dec 1 2019 |
Keywords
- Acquired immune deficiency syndrome
- Cancer
- Chemotherapy
- HIV
- Therapy-related myelodysplastic syndromes (t-MDS)
ASJC Scopus subject areas
- Pathology and Forensic Medicine
- Histology
- Hematology